Find an Eye MD near you!

Shire announced that lifitegrast met its primary and secondary endpoints

Investigators found that the latest concept in the prevention of post-cataract posterior capsule opacification appears promising.

Adherence patterns established during the first year of treatment typically don’t change over time.

University of Leeds researcher is developing an IOL for presbyopia made from liquid crystal.

Citron Research accuses Canadian-based pharmaceutical company Valeant of massive fraud.

FDA has requested an additional information for Shire’s dry eye disease drug, lifitegrast.


Diagnose This: Minimizing ocular movement during phacoemulsification

◦Attention colleagues! Please reach out to your member of Congress regarding the rising drug prices and lack of tra…

Looks like a great weekend for the WVAEPS 2018 Scientific Conference at the Greenbrier!!! Hope you made your regis…

Suffering eye strain at work? Follow these tips from the American Academy of Ophthalmology to get some relief.